Published in final edited form as:

Biochemistry. 2011 July 12; 50(27): 5971–5978. doi:10.1021/bi200142x.

Amyloid of the *Candida albicans* Ure2p prion domain is infectious and has an in-register parallel β -sheet structure†

Abbi Engel^{1,2}, Frank Shewmaker¹, Herman K. Edskes¹, Fred Dyda³, and Reed B. Wickner^{1,*}

¹ Laboratory of Biochemistry and Genetics, National Institute of Diabetes Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0830

² Biochemistry and Molecular Biology Dept., Georgetown University Medical School, Washington, DC

³ Laboratory of Molecular Biology, National Institute of Diabetes Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0830

Abstract

Ure2p of *Candida albicans* (Ure2^{albicans} or CaUre2p) can be a prion in *Saccharomyces cerevisiae*, but the Ure2p of *Candida glabrata* (Ure2^{glabrata}) cannot, even though the Ure2^{glabrata} N-terminal domain is more similar to that of the *S. cerevisiae* Ure2p (Ure2^{cerevisiae}) than is Ure2^{albicans}. We show that the N-terminal N/Q-rich prion domain of Ure2^{albicans} forms amyloid that is infectious, transmitting [URE3alb] to *S. cerevisiae* cells expressing only the *C. albicans* Ure2p. Using solid-state NMR of selectively labeled *C. albicans* Ure2p^{1–90}, we show that this infectious amyloid has an in-register parallel β -sheet structure, like that of the *S. cerevisiae* Ure2p prion domain and other *S. cerevisiae* prion amyloids. In contrast, the N/Q-rich N-terminal domain of Ure2^{glabrata} does not readily form amyloid, and that formed on prolonged incubation is not infectious.

A prion is an infectious protein, a protein that can transmit an infection without a required nucleic acid. The non-chromosomal genes [URE3] and [PSI+] were identified as prions of Ure2p and Sup35p of *S. cerevisiae* based on their unique genetic properties: (i) reversible curability, (ii) prion generation induced by overproduction of the corresponding protein and (iii) phenotype of prion similar to that of mutants in the corresponding gene needed for maintaining the prion (1). [PIN+] was detected as a non-chromosomal factor needed for inducing [PSI+] appearance by overproduction of Sup35p (2), and shown to be a prion of Rnq1p by the above genetic criteria (3). The [SWI+] and [OCT+] prions (4, 5) were uncovered because their respective proteins, Swi1p and Cyc8p, were found, when overproduced, to have properties like the [PIN+] prion. [MOT3+] was found in a screen of proteins with Q/N rich regions (6). Each of these prions is based on self-propagating amyloid formation by a Q/N - rich protein domain (the prion domain) (e.g. (7–9).

Prions of Ure2p from other *Saccharomyces* species have also been described (10–13), but the Ure2p of *Saccharomyces castellii* cannot be a prion in *S. cerevisiae* (13). When expressed in *S. cerevisiae*, the Ure2p's of *Candida albicans*, *Kluyveromyces lactis* and *Schizosaccharomyces pombe* were reported unable to form a prion, even after

†This work was supported by the Intramural Program of the National Institute of Diabetes Digestive and Kidney Diseases of the National Institutes of Health.

*Corresponding author: Reed B. Wickner, Bldg. 8, Room 225, NIH; 8 Center Drive MSC0830; Bethesda, MD 20892-0830; Phone: 301-496-3452; Fax: 301-402-0240; wickner@helix.nih.gov.

Supporting Information Available. An alignment of the prion domains of Ure2p from *S. cerevisiae*, *C. albicans* and *C. glabrata* is shown in Fig. S1. This material is available free of charge via the Internet at <http://pubs.acs.org>.

overexpression of the respective putative prion domain (11), and the *K. lactis* Ure2p cannot be a prion in *K. lactis* (14). Sup35 domains N, M and C, from N- to C-terminus, are the prion domain (necessary for normal mRNA turnover (15)), a charged middle domain and the C domain necessary for translation termination (9). The N-terminal domains of Sup35 of several yeast species, including *Candida albicans*, can be prion domains when fused to the *S. cerevisiae* C domain (16–18). This is a significant qualification because prion-forming ability of prion domains of Ure2p, Sup35p and HET-s are consistently inhibited by the presence of the remainder of the molecule (8, 19, 20), perhaps by some stabilizing effect. Hsp104 is a disaggregating chaperone that is necessary for the propagation of each of the amyloid-based yeast prions (2, 4, 5, 21, 22). Its role appears to be that of breaking amyloid filaments to form new prion 'seeds' (23). The *Candida albicans* Hsp104 homolog is capable of substituting for the *S. cerevisiae* Hsp104 in propagating [PSI⁺], suggesting that *C. albicans* may have an environment compatible with prion propagation (24).

Amyloid is a filamentous protein polymer that is rich in β -sheet, shows special dye-binding properties and is usually more protease resistant than the non-amyloid form of the protein. The amyloids of the prion domains of *S. cerevisiae* Ure2p, Sup35p and Rnq1p are infectious (25–28), and each has an in-register parallel β -sheet structure (29–31). Measurements of mass per unit length for each are consistent with this structure and inconsistent with a β -helix model (32–34), and the fact that the Ure2p and Sup35p prion domains may each be shuffled in sequence and yet still form prions predicts the same structure (35–37). The in-register parallel β -sheet structure also provides a simple explanation of prion variants, with the different locations of the folds of the β -sheet 'inherited' by new molecules joining the end of the filament (38, 39). In brief, the same hydrogen bonds and hydrophobic interactions between identical side chains of residues aligned in the parallel in-register beta sheets that hold the beta strands in-register, will direct the monomer joining the end of the filament to acquire the same conformation as the other molecules already in the filament. The location of turns (folds of the sheet) and the extent of β -sheet structure will be faithfully propagated, but may differ among prion variants.

We have found that the full length *C. albicans* Ure2 protein can form a [URE3] prion in *S. cerevisiae*, but the *C. glabrata* Ure2p cannot (40). Here we show that the *C. albicans* Ure2p prion domain forms amyloid more readily than that of *C. glabrata*, which forms amyloid only over years. Moreover, the *C. albicans* Ure2p prion domain amyloid is infectious, transmitting [URE3alb] to *S. cerevisiae* cells expressing *C. albicans* Ure2p. We present solid-state NMR data suggesting that, like the *S. cerevisiae* prion domains, the *C. albicans* Ure2p prion domain forms amyloid with an in-register parallel β -sheet structure.

EXPERIMENTAL PROCEDURES

Yeast strains and media

S. cerevisiae strain BY302 (*MATa his3 leu2 trp1 CaURE2 P_{DAL5}:ADE2 P_{DAL5}:CAN1 kar1*) and BY304 (*MATa his3 leu2 trp1 CgURE2 P_{DAL5}:ADE2 P_{DAL5}:CAN1 kar1*) contain the *cerevisiae* URE2 ORF perfectly replaced by the *C. albicans* and *C. glabrata* URE2 ORFs, respectively (40). Strain YHE1161 is BY302 carrying [URE3alb] (40). Rich medium (YPAD) contains 1% yeast extract, 2% peptone, 2% dextrose, 2% agar and 0.4 g/l adenine sulfate. Minimal medium (SD) contains 0.67% Difco Yeast Nitrogen Base without Amino Acids, 2% dextrose, and 2% agar. YES medium, for scoring [URE3], contained 0.5% yeast extract, 3% dextrose, 30 mg/l tryptophan and 2% agar.

Plasmid constructions

C. albicans and *C. glabrata* URE2 expression vectors were all constructed in pET vector backbones with either the N-terminal domain (or “PD”) or the full length proteins attached to a C-terminal His-6 tag (Table 1).

Transfection

Strains BY302 and BY304 were used as transfection recipients using the method of Brachmann et al. (27, 41). Clones were selected for transformation using pRS425 (42). Filaments or extracts of the [URE3alb.] strain YHE1161 (40) were sonicated three times for 20 seconds each at output level 2–3 with 20–30% duty cycle (Branson Sonifier 250) with cooling on ice between sonications.

Purification of *C. albicans* and *C. glabrata* Ure2p and Ure2p N-terminal domains

Plasmids in BL21 (DE3) RIPL (Stratagene) were grown overnight with 34ug/mL chloramphenicol, 50ug/mL streptomycin, and 100ug/mL ampicillin and inoculated into LB medium, or synthetic complete medium(43) with 200 mg/l of Ile-1-¹³C or Val-1-¹³C or 1g/l of Ala-3-¹³C for site-specific labeling. Mass spectrometry showed that Ala residues were 60% labeled and no significant leakage of label into other amino acids was detected. The latter medium without amino acids, but containing 2 g/l ¹⁵NH₄Cl and 5 g/l uniformly ¹³C-labeled glucose was used for uniform labeling of CaUre2p^{1–90}. At A₆₀₀ ~0.6–1.0 1mM isopropyl-β-D-thiogalactosidase (IPTG) was added and after four hours of further growth, cells were harvested. CaUre2p^{1–90} or CgUre2p^{1–100} were obtained from bacteria lysed by vigorous agitation with 6 M guanidine-HCl, 0.1 M Tris, 150 mM NaCl, pH 8.0–8.5 and incubation at room temperature for 1–2 hours. Full length protein of both *C. glabrata* and *C. albicans* was obtained by lysing cells using a French pressure cell in 50 mM NaHPO₄, 300 mM NaCl pH8 with Roche protease inhibitors (complete EDTA-free). Lysates were cleared of cell debris by ultracentrifugation at 30000 rpm for 30–60min (Beckman-Coulter Optima L-90k Ultracentrifuge, Type 45Ti rotor). Cleared lysates were incubated with nitrilotriacetic acid (NiNTA) agarose (Qiagen) at room temperature with gentle agitation, loaded into a glass column (Biorad), washed with urea buffer (8M urea, 0.1M Tris, 150mMNaCl) for the N-terminal fragments or 50 mM NaHPO₄, 300 mM NaCl pH8 for the full length proteins. After washing the column with the same buffer with 20mM imidazole, proteins were eluted with the same buffer with 200 mM imidazole. Protein concentrations were roughly determined by 4–12% NuPAGE Bis-tris gel (Invitrogen) stained with SimplyBlue Safestain (Coomassie G-250 stain, Invitrogen) and by BCA assay (Pierce).

If necessary, further purification used a Q-sepharose column (HighQ, Biorad). Fractions containing protein were diluted 5-fold with zero salt urea buffer (8 M urea, 50mM Tris) and loaded onto the Q-column. The column was washed with same zero salt urea buffer. Protein was eluted with a gradient of 0–200mM NaCl added in the same buffer.

Amyloid formation

Selected fractions were pooled and concentrated and dialyzed against 50 mM Tris Cl, 150 mM NaCl pH 8 to induce amyloid formation. Filaments were formed at room temperature with agitation for two days to one week. A variety of buffers were tested in an effort to induce filament formation by *C. glabrata* Ure2p^{1–100}. Buffers tested included 5 mM KPO₄, 150 mM NaCl, pH 6.8; 50 mM TrisCl, 300 mM NaCl, pH 8; 3 M urea, 0.1 M Tris Cl, 150 mM NaCl, pH 8.3; 20 mM Tris Cl, 200 mM KCl, pH 8; 50 mM Tris Cl, 150 mM NaCl, pH 8. Prolonged incubation of *C. glabrata* Ure2p^{1–100} produced only limited amyloid (see Results) and SDS gel analysis of the still soluble material showed no change in protein pattern after 2 years.

X-ray fiber diffraction

Sample preparation, X-ray fiber diffraction procedure and data analysis were carried out as described previously (31).

Electron microscopy

Ten μ l of a suitable dilution of filaments was deposited on a carbon-coated copper grid, washed once with water and stained with 2% uranyl acetate for two minutes. The stain was blotted off, the grid allowed to air dry and images obtained using an FEI Morgagni transmission electron microscope at 80 kV.

Solid-state NMR

Solid-state NMR experiments on selectively labeled *CaUre2p*¹⁻⁹⁰ were carried out on a Varian InfinityPlus spectrometer at 9.39 T (100.4 MHz ¹³C NMR frequency) using magic angle spinning (MAS) in 3.2 mm rotors at room temperature. Although some cooling was used, rotors spun at 20 kHz may warm up to ~40°C. One dimensional spectra were acquired at 20 kHz MAS using ¹H-¹³C cross polarization (44) and two-pulse phase-modulated ¹H decoupling (45). The dipolar recoupling measurements were carried out at 20 kHz MAS using the PITHIRDS-CT method (46) with pulsed spin-lock detection for improved signal-to-noise ratios (47). *C.a.Ure2p*¹⁻⁹⁰ filament samples were washed with water, lyophilized and packed in thick-walled 3.2 mm rotors. ¹³C T₂ values under PITHIRDS-CT measurement conditions were measured by incrementing the total pulse sequence length while keeping the effective recoupling time equal to zero, to assure that no less than 25% of the signal remained at the end of the dipolar recoupling period.

PITHIRDS-CT data for an unlabeled sample of *C.a.Ure2p*¹⁻⁹⁰ were measured (Fig. 3A) and used to correct for the 1% natural abundance ¹³C, assuming linear signal decay: natural abundance signal = $S_{na} = 100 - 0.2 t$, where t is the effective dipolar dephasing time in milliseconds. The number of natural abundance ¹³C nuclei per *C.a.Ure2p*¹⁻⁹⁰ molecule, N_{na} , is $0.011 \times (\text{total sites} - \text{labeled nuclei})$, where total sites is 139 carbonyls or 30 methyls. Labeled nuclei, N_{label} , was 2 for Ile-1-¹³C, 5 for Val-1-¹³C and 2 for Ala-3-¹³C. The fraction of natural abundance ¹³C is $F_{na} = N_{na}/(N_{label} + N_{na})$. Experimentally determined ¹³C T₂ values were used to correct the magnitude of the natural abundance signal when its T₂ differed from that of the specifically labeled sample. Raw PITHIRDS-CT data were corrected according to the following: $S(t) = (S_{raw} - F_{na} * (100 - 0.2t)) / (1 - F_{na})$.

Two dimensional NMR experiments with uniformly ¹⁵N, ¹³C-labeled rehydrated amyloid filaments of *C.a.Ure2p*¹⁻⁹⁰ in 3.2 mm rotors were carried out at 17 kHz MAS. The mixing period comprised 48 rotor periods (2.82 ms) of finite pulse RFDR (radio-frequency driven recoupling) with 18 μ s ¹³C π pulses. Continuous proton decoupling at 110 kHz was used during the mixing period, and TPPM (two pulse phase-modulated) decoupling (45), also at 110 kHz, during the t₁ and t₂ periods. 2D NMR data were analyzed using NMRPipe software (48) and displayed relative to tetramethylsilane using an Ala-1-¹³C standard.

Results

C. albicans Ure2p¹⁻⁹⁰ readily forms amyloid

The N-terminal domain of the *C. albicans* Ure2p is presumed to be the prion domain based on its Q/N richness and the finding that its overproduction induces the *de novo* appearance of [URE3] (40). We chose to study *C.a.Ure2p*¹⁻⁹⁰ because beyond residue 90, homology with the C-terminal domain of the *S. cerevisiae* Ure2p begins. *C.a.Ure2p*¹⁻⁹⁰H₆ was purified under denaturing conditions from *E. coli* (see Methods) and allowed to form filaments in the absence of denaturant. Filaments formed within a few days of gentle agitation at room

temperature in 50 mM Tris Cl pH 8.0, 150 mM NaCl (Fig. 1). Fibrils of *C.a.* Ure2p¹⁻⁹⁰H₆ were straight, apparently unbranched and about 6 nm in diameter, with frequent lateral association (Fig. 1). Some “twisted pairs” were occasionally observed (Fig. 1A). These filaments showed yellow-green birefringence on staining with Congo Red (Fig. 1B), another trait typical of amyloid.

X-ray fiber diffraction of the *C. albicans* Ure2p¹⁻⁹⁰ fibers shows an intense sharp band at 4.7 Å and a broader band centered at 9.4 Å (Fig. 1C, D). This pattern is diagnostic of β-sheet structure with the 4.7 Å peak due to reflections between adjacent β-strands and the 9.4 Å peak reflects either the distance between neighboring β-sheets, or possibly the distance between alternate beta strands (2×4.7 Å).

In contrast to the rapid formation of amyloid filaments by the *C. albicans* Ure2 N-terminal domain, that of *C. glabrata* only slowly and partially did so, in spite of many attempts under a variety of buffer conditions. After about 2 years of incubation at 4°C, filaments of *C. glabrata* Ure2p¹⁻¹⁰⁰ were observed, but the bulk of the protein remained soluble. Even seeding with a sonicated portion of these filaments did not promote filament formation after incubation for 2 more months in Tris or potassium phosphate buffers. X-ray fiber diffraction of the fibers formed showed a typical β-sheet pattern and the fibers showed birefringence on staining with Congo Red (not shown). Full length *C. glabrata* Ure2p did not form detectable amyloid under the conditions used.

***C. albicans* Ure2p¹⁻⁹⁰ filaments are infectious producing several [URE3^{Ca}] variants**

Ure2p is a negative regulator of nitrogen catabolism, inhibiting the transcription of genes for transporters and enzymes needed for the utilization of poor nitrogen sources when a good nitrogen source is available (reviewed in (49, 50)). Transcription of *DAL5*, encoding the allantoin transporter, is particularly strongly repressed by Ure2p action (51). By replacing the *ADE2* promoter with that of *DAL5*, we can use adenine auxotrophy (and red colony color on adenine-limiting media) as a sign of Ure2p activity (27, 52). Thus, [URE3] clones are Ade⁺ and white because of Ure2p inactivity, while [ure-o] clones are Ade⁻ and red.

Various sonicated filament preparations were introduced (27) into *S. cerevisiae* strains in which the *URE2* gene had been replaced by that of *C. albicans* (BY302) or of *C. glabrata* (BY304) (40). Cells that have taken up a DNA plasmid (pRS425) are selected as Leu⁺ colonies and these are tested on -Ade plates. Those that are Ade⁺ (possible [URE3] transfectants) are grown on 3 mM guanidine to test for curing to confirm that the Ade⁺ is due to prion infection (Table 2). Guanidine inhibits Hsp104 (53), a disaggregating chaperone required for propagation of [URE3alb] (40) as it is for other yeast prions. We found that a substantial portion of Leu⁺ clones had acquired [URE3alb] after infection with either filaments of *C.a.*Ure2p¹⁻⁹⁰ or with an extract of the [URE3alb] strain YHE1161 (Table 2). Infection required that the cell's *URE2* gene encode the same Ure2p as the infecting material, so *S.c.*Ure2p¹⁻⁸⁹ filaments and *C.g.*Ure2p¹⁻¹⁰⁰ filaments were not infectious for cells carrying the *C. albicans* *URE2*(Table 2).

This infectivity of *C.a.*Ure2p¹⁻⁹⁰ filaments shows that Ure2p¹⁻⁹⁰ includes the prion domain and is consistent with the ability of overexpression of this region to induce [URE3alb] formation *in vivo* (40). Restreaking Ade⁺ [URE3alb] clones on adenine-limiting medium showed that the transfectants harbored an array of prion variants, differing in their stability and in the intensity of the Ade⁺ phenotype (Fig. 2), similar to results observed for *S. cerevisiae* Ure2p filaments (27).

Solid-state NMR studies of *C. albicans* Ure2p¹⁻⁹⁰ amyloid

The infectivity of the *C.a.*Ure2p¹⁻⁹⁰ filaments implies that the structural studies we report here are relevant to the prion phenomenon. One dimensional NMR spectra of dry fibrils of *C.a.*Ure2p¹⁻⁹⁰ labeled with Val-1-¹³C, Ile-1-¹³C, Ala-3-¹³C or unlabeled (natural abundance) are shown in Fig. 3. Note that we have shown that the infectivity of amyloid fibrils of Ure2p^{cerevisiae} and Sup35NM are unaffected by drying (54). The Ile-1-¹³C - labeled amyloid showed a major peak (85%) at 172.6 ppm, whereas the chemical shift expected for random coil structure is 174.7 ppm (55). For Val-1-¹³C - labeled *C.a.*Ure2p¹⁻⁹⁰ amyloid the major peak (68%) was at 171.9 ppm while the random coil value is 174.6 ppm. In general, carbonyl carbon resonance frequencies are shifted to lower values for residues in β -sheet structure, and shifted up for α -helical residues (55). These results indicate that most Ile and Val residues are in β -sheet structure. The X-ray fiber diffraction studies (above) indicate that β -sheet structure is more extensive than the few residues that could be examined individually by solid-state NMR.

In an amyloid with parallel in-register β -sheet structure, each residue is aligned in a row of identical residues extending along the long axis of the fibril. Therefore, if a particular amino acid, say isoleucine, is fully labeled specifically in the carbonyl carbon (Ile-1-¹³C), then the distance from each ¹³C label to the nearest neighbor ¹³C will be the 4.7 Å distance between main chains in the β sheet (56, 57) reviewed by (58). In other forms of β -sheet -antiparallel, β -helix or parallel out-of-register - the distance is far greater than 4.7 Å. This distance is measured by a dipolar recoupling experiment, such as the PITHIRDS-CT method used here (46). In this experiment, the rate of signal decay is roughly proportional to the inverse of the cube of the distance from one labeled atom to its nearest labeled neighbor.

An amyloid sample of *C.a.*Ure2p¹⁻⁹⁰ labeled with Ile-1-¹³C showed signal decay reflecting a nearest neighbor distance of about 5 Å indicating a parallel in-register structure (Fig. 4A). About 1.1% of all carbon is ¹³C, so that the same experiment can be done using unlabeled amyloid. Of course, in this case, the nearest neighbor ¹³C will nearly always be quite distant, and accordingly, a very slow signal decay was observed (Fig. 4A). Val-1-¹³C - labeled *C.a.*Ure2p¹⁻⁹⁰ amyloid showed an apparent biphasic signal decay curve, suggesting that some Val residues are in an in-register parallel structure and others are not (Fig. 4A). This result is consistent the 1D NMR spectrum of this material which indicates ~2/3 of Val residues are in β -sheet structure and the remainder are not (Fig. 3).

In another experiment, we labeled the methyl groups of the two Ala residues of *C.a.*Ure2p¹⁻⁹⁰ and formed amyloid *in vitro*. For a parallel in-register β -sheet, a nearest-neighbor distance of ~5 Å is expected. Since adjacent side chains in a β -strand point in opposite directions, if the parallel β -sheet is out of register by even a single residue, the nearest neighbor distance for this side-chain label will be > 8 Å. The rapid signal decay seen in a PITHIRDS-CT experiment with Ala-3-¹³C *C.a.* Ure2p¹⁻⁹⁰ (Fig. 4B) is again indicative of an in-register parallel structure.

A two dimensional ¹³C-¹³C solid state NMR experiment using uniformly ¹³C-labeled rehydrated *C.a.* Ure2p¹⁻⁹⁰ amyloid showed broad peaks which could only be assigned amino acid type but not to individual residues (Fig. 5). This result indicates heterogeneity of structure, consistent with the heterogeneity of prion variant observed on transfection of yeast cells (Fig. 2).

Discussion

Our previous work showed that *C.a.*Ure2p can form a prion in *S. cerevisiae*, but that *C.g.*Ure2p cannot (40). Here we find that *C.a.*Ure2p¹⁻⁹⁰ readily forms amyloid, but that

C.g.Ure2p^{1–100} only forms a small amount of amyloid over a period of two years, providing a possible explanation for the inability of *C.g.Ure2p* to be a prion. Of course, it is possible that there exists some other buffer condition under which *C.g.Ure2p* would readily form amyloid. Whether amyloid forming ability (or lack of it) will be a general explanation of whether or not a protein can be a prion will require examination of a wide range of species.

The *C.a.Ure2p*^{1–90} amyloid formed is infectious for *S. cerevisiae* expressing *C.a.Ure2p* in place of the *S.c.Ure2p*, but we were not successful in inducing *C.g.Ure2p* to form [URE3] by introduction of the small amount of available *C.g.Ure2p*^{1–100} amyloid. Of course it remains possible that with larger amounts of *C. glabrata* amyloids, or different conditions of amyloid formation, infection might be observed. The infection produces a variety of [URE3alb] variants with varying degrees of strong or weak phenotype and stable or unstable inheritance. This array of prion variants presumably reflects an array of amyloid structures, and the wide peaks we observe in 2D solid state NMR experiments (Fig. 5) are likely a reflection of such structural heterogeneity.

Our structural studies indicate that the amyloid fibers formed *in vitro* by *C.a.Ure2p*^{1–90} have an architecture like that of the other amyloid-based yeast prions, namely, an in-register parallel β -sheet. The 6 nm diameter of the filaments of *C.a.Ure2p*^{1–90} indicates that the sheet is multiply folded along its long axis, since a fully extended monomer would be approximately 30 nm in length. More detailed structural studies will be needed to ascertain the location of the folds and other details of the structure, but this will require development of a method to prepare structurally homogeneous filaments.

While mammalian prions are uniformly fatal, those of yeast and fungi are not, so that whether prions are diseases or of some adaptive value must be judged by other evidence. The conservation of prion formation among closely related species would not prove that it has a function for the host (any more than the conservation of occasional broken wings among birds suggests a benefit). However, the failure of conservation among close relatives would argue against a functional role for prion formation. Residues 10–39 of the *S. cerevisiae* Ure2p prion domain is conserved among a range of yeasts (10, 11, 59), and this led Harrison et al. to propose that this region is conserved to enable prion formation (59). Ross et al. demonstrated that sequence is of little importance for prion formation by Ure2p or by Sup35p (35, 36), so the conserved part of the Ure2p prion domain is not likely conserved for prion formation: a need for prion formation would not result in conservation of the sequence. Moreover, *C. glabrata* is closely related to *S. cerevisiae* and *C.g.Ure2p* has the conserved prion domain sequence (Fig. S1), but does not form prions. In contrast, *C. albicans* is more distantly related to *S. cerevisiae* and its Ure2p lacks the conserved sequence (Fig. S1), but we find that it readily forms prions. This suggests that the sequence is conserved for some other reason, perhaps for the stabilization of the full length protein by the prion domain as demonstrated for *S. cerevisiae* (60).

While definitive data is scarce, the pattern seems to be that prion-forming ability of a given protein is scattered, rather than concentrated among close relatives. For example, the full length *S. castellii* Ure2p cannot form a prion in *S. cerevisiae* (13), but the Ure2p's of several other *Saccharomyces* species can form [URE3]. One fourth of wild *S. cerevisiae* strains tested had a large deletion in their Sup35 prion domains making them unable to form the [PSI⁺] prion (61). Several N-terminal domains of Sup35 of other species fused to the *S. cerevisiae* Sup35C have been found to be able to act as prion domains (16–18). However, it is known that for Ure2p, Sup35p and HET-s, the prion domain is substantially stabilized by the remainder of the molecule (8, 19, 20), so that the context of the full length molecule is important.

The absence of the [URE3] and [PSI⁺] prions in wild strains, the inability of some species closely related to *S. cerevisiae* to form these prions, the fact that the 'prion domains' have clear-cut non-prion functions and the rapid evolution of the prion domains producing species barriers all indicate that these are yeast diseases (reviewed in (39)). The cells themselves signal their displeasure at infection with [URE3] and [PSI⁺] by undergoing the stress-response, inducing at least Hsp70s and Hsp104 (62, 63). Moreover, the existence of lethal and very pathological variants of [PSI⁺] and [URE3] further argue against an adaptive role for these prions (64). The study of these yeast prion diseases is making important contributions to our understanding of mammalian prion diseases and amyloid diseases in general.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank Rob Tycko for help with solid-state NMR.

Abbreviations used

Ure2^{albicans}	the protein encoded by the <i>URE2</i> gene of <i>Candida albicans</i>
[URE3^{alb}]	a prion (infectious protein) of Ure2 ^{albicans}
NMR	nuclear magnetic resonance

References

1. Wickner RB. [URE3] as an altered *URE2* protein: evidence for a prion analog in *S. cerevisiae*. *Science*. 1994; 264:566–569. [PubMed: 7909170]
2. Derkatch IL, Bradley ME, Zhou P, Chernoff YO, Liebman SW. Genetic and environmental factors affecting the *de novo* appearance of the [PSI⁺] prion in *Saccharomyces cerevisiae*. *Genetics*. 1997; 147:507–519. [PubMed: 9335589]
3. Derkatch IL, Bradley ME, Hong JY, Liebman SW. Prions affect the appearance of other prions: the story of [PIN]. *Cell*. 2001; 106:171–182. [PubMed: 11511345]
4. Du Z, Park K-W, Yu H, Fan Q, Li L. Newly identified prion linked to the chromatin-remodeling factor Swi1 in *Saccharomyces cerevisiae*. *Nat Genet*. 2008; 40:460–465. [PubMed: 18362884]
5. Patel BK, Gavin-Smyth J, Liebman SW. The yeast global transcriptional co-repressor protein Cyc8 can propagate as a prion. *Nat Cell Biol*. 2009; 11:344–349. [PubMed: 19219034]
6. Alberti S, Halfmann R, King O, Kapila A, Lindquist S. A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. *Cell*. 2009; 137:146–158. [PubMed: 19345193]
7. Masison DC, Maddelein ML, Wickner RB. The prion model for [URE3] of yeast: spontaneous generation and requirements for propagation. *Proc Natl Acad Sci USA*. 1997; 94:12503–12508. [PubMed: 9356479]
8. Masison DC, Wickner RB. Prion-inducing domain of yeast Ure2p and protease resistance of Ure2p in prion-containing cells. *Science*. 1995; 270:93–95. [PubMed: 7569955]
9. TerAvanesyan A, Dagkesamanskaya AR, Kushnirov VV, Smirnov VN. The *SUP35* omnipotent suppressor gene is involved in the maintenance of the non-Mendelian determinant [psi⁺] in the yeast *Saccharomyces cerevisiae*. *Genetics*. 1994; 137:671–676. [PubMed: 8088512]
10. Edskes HK, Wickner RB. Conservation of a portion of the *S. cerevisiae* Ure2p prion domain that interacts with the full - length protein. *Proc Natl Acad Sci USA*. 2002; 99(Suppl 4):16384–16391. [PubMed: 12177423]

11. Baudin-Baillieu A, Fernandez-Bellot E, Reine F, Coissac E, Cullin C. Conservation of the prion properties of Ure2p through evolution. *Mol Biol Cell*. 2003; 14:3449–3458. [PubMed: 12925776]
12. Talarek N, Maillet L, Cullin C, Aigle M. The [URE3] prion is not conserved among *Saccharomyces* species. *Genetics*. 2005; 171:23–54. [PubMed: 15956663]
13. Edskes HK, McCann LM, Hebert AM, Wickner RB. Prion variants and species barriers among *Saccharomyces* Ure2 proteins. *Genetics*. 2009; 181:1159–1167. [PubMed: 19124570]
14. Safadi RA, Talarek N, Jacques N, Aigle M. Yeast prions: could they be exaptations? The *URE2*/[URE3] system in *Kluyveromyces lactis*. *FEMS Yeast Res*. 2011; 11:151–153. [PubMed: 21235712]
15. Hosoda N, Kobayashii T, Uchida N, Funakoshi Y, Kikuchi Y, Hoshino S, Katada T. Translation termination factor eRF3 mediates mRNA decay through the regulation of deadenylation. *J Biol Chem*. 2003; 278:38287–38291. [PubMed: 12923185]
16. Chernoff YO, Galkin AP, Lewitin E, Chernova TA, Newnam GP, Belenkiy SM. Evolutionary conservation of prion-forming abilities of the yeast Sup35 protein. *Molec Microbiol*. 2000; 35:865–876. [PubMed: 10692163]
17. Kushnirov VV, Kochneva-Pervukhova NV, Cechenova MB, Frolova NS, Ter-Avanesyan MD. Prion properties of the Sup35 protein of yeast *Pichia methanolica*. *EMBO J*. 2000; 19:324–331. [PubMed: 10654931]
18. Santoso A, Chien P, Osherovich LZ, Weissman JS. Molecular basis of a yeast prion species barrier. *Cell*. 2000; 100:277–288. [PubMed: 10660050]
19. Kochneva-Pervukhova NV, Poznyakovski AI, Smirnov VN, Ter-Avanesyan MD. C-terminal truncation of the Sup35 protein increases the frequency of de novo generation of a prion-based [*PSI*⁺] determinant in *Saccharmyces cerevisiae*. *Curr Genet*. 1998; 34:146–151. [PubMed: 9724418]
20. Balguerie A, Dos Reis S, Ritter C, Chaignepain S, Coulary-Salin B, Forge V, Bathany K, Lascu I, Schmitter JM, Riek R, Saupé S. Domain organization and structure-function relationship of the HET-s prion protein of *Podospora anserina*. *Embo J*. 2003; 22:2071–2081. [PubMed: 12727874]
21. Chernoff YO, Lindquist SL, Ono BI, Inge-Vechtormov SG, Liebman SW. Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [*psi*⁺]. *Science*. 1995; 268:880–884. [PubMed: 7754373]
22. Moriyama H, Edskes HK, Wickner RB. [URE3] prion propagation in *Saccharomyces cerevisiae*: requirement for chaperone Hsp104 and curing by overexpressed chaperone Ydj1p. *Mol Cell Biol*. 2000; 20:8916–8922. [PubMed: 11073991]
23. Cox BS, Ness F, Tuite MF. Analysis of the generation and segregation of propagons: entities that propagate the [*PSI*⁺] prion in yeast. *Genetics*. 2003; 165:23–33. [PubMed: 14504215]
24. Zenthon JF, Ness F, Cox B, Tuite MF. The [*PSI*⁺] prion of *Saccharomyces cerevisiae* can be propagated by an Hsp104 orthologue from *Candida albicans*. *Eukaryot Cell*. 2006; 5:217–225. [PubMed: 16467463]
25. King CY, Diaz-Avalos R. Protein-only transmission of three yeast prion strains. *Nature*. 2004; 428:319–323. [PubMed: 15029195]
26. Tanaka M, Chien P, Naber N, Cooke R, Weissman JS. Conformational variations in an infectious protein determine prion strain differences. *Nature*. 2004; 428:323–328. [PubMed: 15029196]
27. Brachmann A, Baxa U, Wickner RB. Prion generation *in vitro*: amyloid of Ure2p is infectious. *Embo J*. 2005; 24:3082–3092. [PubMed: 16096644]
28. Patel BK, Liebman SW. “Prion proof” for [*PIN*⁺]: infection with *in vitro*-made amyloid aggregates of Rnq1p-(132–405). induces [*PIN*⁺]. *J Mol Biol*. 2007; 365:773–782. [PubMed: 17097676]
29. Shewmaker F, Wickner RB, Tycko R. Amyloid of the prion domain of Sup35p has an in-register parallel β -sheet structure. *Proc Natl Acad Sci USA*. 2006; 103:19754–19759. [PubMed: 17170131]
30. Baxa U, Wickner RB, Steven AC, Anderson D, Marekov L, Yau WM, Tycko R. Characterization of β -sheet structure in Ure2p1–89 yeast prion fibrils by solid state nuclear magnetic resonance. *Biochemistry*. 2007; 46:13149–13162. [PubMed: 17953455]
31. Wickner RB, Dyda F, Tycko R. Amyloid of Rnq1p, the basis of the [*PIN*⁺] prion, has a parallel in-register β -sheet structure. *Proc Natl Acad Sci U S A*. 2008; 105:2403–2408. [PubMed: 18268327]

32. Baxa U, Taylor KL, Wall JS, Simon MN, Cheng N, Wickner RB, Steven A. Architecture of Ure2p prion filaments: the N-terminal domain forms a central core fiber. *J Biol Chem.* 2003; 278:43717–43727. [PubMed: 12917441]
33. Diaz-Avalos R, King CY, Wall JS, Simon M, Caspar DLD. Strain-specific morphologies of yeast prion amyloids. *Proc Natl Acad Sci U S A.* 2005; 102:10165–10170. [PubMed: 16006506]
34. Chen B, Thurber KR, Shewmaker F, Wickner RB, Tycko R. Measurement of amyloid fibril mass-per-length by tilted-beam transmission electron microscopy. *Proc Natl Acad Sci USA.* 2009; 106:14339–14344. [PubMed: 19706519]
35. Ross ED, Baxa U, Wickner RB. Scrambled prion domains form prions and amyloid. *Mol Cell Biol.* 2004; 24:7206–7213. [PubMed: 15282319]
36. Ross ED, Edskes HK, Terry MJ, Wickner RB. Primary sequence independence for prion formation. *Proc Natl Acad Sci U S A.* 2005; 102:12825–12830. [PubMed: 16123127]
37. Ross ED, Minton AP, Wickner RB. Prion domains: sequences, structures and interactions. *Nat Cell Biol.* 2005; 7:1039–1044. [PubMed: 16385730]
38. Wickner RB, Shewmaker F, Kryndushkin D, Edskes HK. Protein inheritance (prions) based on parallel in-register β -sheet amyloid structures. *Bioessays.* 2008; 30:955–964. [PubMed: 18798523]
39. Wickner RB, Shewmaker F, Edskes H, Kryndushkin D, Nemecek J, McGlinchey R, Bateman D, Winchester C-L. Prion amyloid structure explains templating: how proteins can be genes. *FEMS Yeast Res.* 2010; 10:980–991. [PubMed: 20726897]
40. Edskes HK, Engel A, McCann LM, Brachmann A, Tsai H-F, Wickner RB. Prion-forming ability of Ure2 of yeasts is not evolutionarily conserved. *Genetics.* in press.
41. Brachmann A, Toombs JA, Ross ED. Reporter assay systems for [URE3] detection and analysis. *Methods.* 2006; 39:35–42. [PubMed: 16762564]
42. Christianson TW, Sikorski RS, Dante M, Shero JH, Hieter P. Multifunctional yeast high-copy-number shuttle vectors. *Gene.* 1992; 110:119–122. [PubMed: 1544568]
43. Cai ML, Huang Y, Sakaguchi K, Clore GM, Gronenborn AM, Craigie R. An efficient and cost-effective isotope labeling protocol for proteins expressed in *Escherichia coli*. *J Biomol NMR.* 1998; 11:97–102. [PubMed: 9566315]
44. Pines A, Gibby MG, Waugh JS. Proton-Enhanced Nmr of Dilute Spins in Solids. *J Chem Phys.* 1973; 59:569–590.
45. Bennett AE, Rienstra CM, Auger M, Lakshmi KV, Griffin RG. Heteronuclear Decoupling in Rotating Solids. *J Chem Phys.* 1995; 103:6951–6958.
46. Tycko R. Symmetry-based constant-time homonuclear dipolar recoupling in solid-state NMR. *J Chem Phys.* 2007; 126:064506. [PubMed: 17313228]
47. Petkova AT, Tycko R. Sensitivity enhancement in structural measurements by solid state NMR through pulsed spin locking. *J Mag Res.* 2002; 155:293–299.
48. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a multidimensional spectral processing system based on unix pipes. *J Biomol NMR.* 1995; 6:277–293. [PubMed: 8520220]
49. Magasanik B, Kaiser CA. Nitrogen regulation in *Saccharomyces cerevisiae*. *Gene.* 2002; 290:1–18. [PubMed: 12062797]
50. Cooper TG. Transmitting the signal of excess nitrogen in *Saccharomyces cerevisiae* from the Tor proteins to the GATA factors: connecting the dots. *FEMS Microbiol Revs.* 2002; 26:223–238. [PubMed: 12165425]
51. Rai R, Genbauffe F, Lea HZ, Cooper TG. Transcriptional regulation of the *DAL5* gene in *Saccharomyces cerevisiae*. *J Bacteriol.* 1987; 169:3521–3524. [PubMed: 3301804]
52. Schlumberger M, Prusiner SB, Herskowitz I. Induction of distinct [URE3] yeast prion strains. *Mol Cell Biol.* 2001; 21:7035–7046. [PubMed: 11564886]
53. Jung G, Jones G, Masison DC. Amino acid residue 184 of yeast Hsp104 chaperone is critical for prion-curing by guanidine, prion propagation, and thermotolerance. *Proc Natl Acad Sci USA.* 2002; 99:9936–9941. [PubMed: 12105276]

54. Shewmaker F, Kryndushkin D, Chen B, Tycko R, Wickner RB. Two prion variants of Sup35p have in-register β -sheet structures, independent of hydration. *Biochemistry*. 2009; 48:5074–5082. [PubMed: 19408895]
55. Wishart DS, Bigam CG, Holm A, Hodges RS, Sykes BD. H-1, C-13 and N-15 Random Coil Nmr Chemical-Shifts of the Common Amino-Acids .1. Investigations of Nearest-Neighbor Effects. *J Biomol NMR*. 1995; 5:67–81. [PubMed: 7881273]
56. Benzinger TL, Gregory DM, Burkoth TS, Miller-Auer H, Lynn DG, Botto RE, Meredith SC. Propagating structure of Alzheimer's beta-amyloid(10–35) is parallel beta-sheet with residues in exact register. *Proc Natl Acad Sci U S A*. 1998; 95:13407–13412. [PubMed: 9811813]
57. Antzutkin ON, Balbach JJ, Leapman RD, Rizzo NW, Reed J, Tycko R. Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of beta-sheets in Alzheimer's beta-amyloid fibrils. *Proc Natl Acad Sci U S A*. 2000; 97:13045–13050. [PubMed: 11069287]
58. Tycko R. Molecular structure of amyloid fibrils: insights from solid-state NMR. *Quart Revs Biophys*. 2006; 1:1–55.
59. Harrison LB, Yu Z, Stajich JE, Dietrich FS, Harrison PM. Evolution of budding yeast prion-determinant sequences across diverse fungi. *J Mol Biol*. 2007; 10.1016/j.jmb.2007.1001.1070
60. Shewmaker F, Mull L, Nakayashiki T, Masison DC, Wickner RB. Ure2p function is enhanced by its prion domain in *Saccharomyces cerevisiae*. *Genetics*. 2007; 176:1557–1565. [PubMed: 17507672]
61. Resende CG, Outeiro TF, Sands L, Lindquist S, Tuite MF. Prion protein gene polymorphisms in *Saccharomyces cerevisiae*. *Mol Microbiol*. 2003; 49:1005–1017. [PubMed: 12890024]
62. Jung G, Jones G, Wegrzyn RD, Masison DC. A role for cytosolic Hsp70 in yeast [PSI⁺] prion propagation and [PSI⁺] as a cellular stress. *Genetics*. 2000; 156:559–570. [PubMed: 11014806]
63. Schwimmer C, Masison DC. Antagonistic interactions between yeast [PSI⁺] and [URE3] prions and curing of [URE3] by Hsp70 protein chaperone Ssa1p but not by Ssa2p. *Mol Cell Biol*. 2002; 22:3590–3598. [PubMed: 11997496]
64. McGlinchey R, Kryndushkin D, Wickner RB. Suicidal [PSI⁺] is a lethal yeast prion. *Proc Natl Acad Sci USA*. 2011 epub ahead of print.

Fig. 1. Ure2p¹⁻⁹⁰ of *Candida albicans* forms amyloid *in vitro*. A. Electron micrographs of negatively stained filaments of *Candida albicans* Ure2p¹⁻⁹⁰. Filaments average about 6 nm in diameter. Examples of filaments showing a twisted appearance are shown on the right. B. Yellow-green birefringence of Congo-red stained filaments of *C.a.*Ure2p¹⁻⁹⁰ viewed with a cross-polarizing microscope. C. X-ray fiber diffraction of filaments of *C.a.*Ure2p¹⁻⁹⁰. Diffraction rings due to spacings of 4.7 Å and 9.4 Å are indicated. D. Plot of circular average of diffraction intensity.

Fig. 2. Ade⁺ [URE3alb] transfectants of BY302 were restreaked on YES (adenine-limiting medium). Red colony color indicates adenine deficiency. The differences in stability and color intensity indicate prion variant differences.

Fig. 3. 1D solid-state NMR spectra of *Candida albicans* Ure2p¹⁻⁹⁰ either unlabeled or labeled with Val-1-¹³C, Ile-1-¹³C or Ala-3-¹³C. The inset in the upper right shows a deconvolution of the Val-1-¹³C peak.

Fig. 4. Dipolar recoupling experiments with selectively labeled or natural abundance *C. albicans* Ure2p¹⁻⁹⁰ amyloid using the PITHIRDS-CT method.

Fig. 5.

Aliphatic region of a ^{13}C - ^{13}C 2D solid-state NMR spectrum of wet amyloid formed from $\text{U-}^{13}\text{C}$ *C. albicans* Ure2p¹⁻⁹⁰. Assignments shown do not exclude the presence in the same broad peak of signals from other residue types.

Table 1

C. albicans and *C. glabrata* URE2 expression plasmids with primers used for their construction. All expression plasmids are derivatives of pUB6 [gift from Ulrich Baxa; modified pET17-b (Novagen)] except for pAE5, which is derived from pET21-b (Novagen). Italics indicate the His-6 tag, underlined portions are restriction sites.

Plasmid	URE2 Expression Construct	5' primer	3' primer
pAE1	URE2 ^{glabrata} -H6 (Full length)	HE297 TAAGGATCCCAAATGGGTGA CTCACGCAAT	AE68: GTTCTCGAGTTAATGGTGATGGTGAT GATGCTCTCCGCGAAGGGC
pAE2	URE2 ^{glabrata} 1-100 -H6 ("PD")	HE297 TAAGGATCCCAAATGGGTGA CTCACGCAAT	AE88: CTTCTCGAGTTAATGGTGATGGTGAT GATGATACTCCATCGGGTTGAATT
pAE3	URE2 ^{albicans} 1-89 -H6 ("PD")	AE100: AACTCTAGAAATAATTTTGTT TAACTTTAAGAAGGAGATCT ATGATGTCTACTGATCAAC	AE101: CTTCTCGAGTTAATGGTGATGGTGAT GATGTTGTTGTTGTTGAGTAGAAGC
pAE4	URE2 ^{albicans} - H6 (Full length)	AE100: AACTCTAGAAATAATTTTGTT TAACTTTAAGAAGGAGATCT ATGATGTCTACTGATCAAC	AE102: CTTCTCGAGTTAATGGTGATGGTGAT GATGATCTCCACGTAAAGCGCGTTT
pAE5	URE2 ^{albicans} 1-90 - H6 ("PD")	NdeAlbURE2 AAAACATATGATGTCTACTG ATCAACATAT	cXhoAlbURE2 TGGCTCGAGTTTAAATGGTGATGATG GTGATGTCTTGATTGTTGTTGTTGA GTAGAAGCTT

Table 2
***Candida albicans* prion domain (Ure2p¹⁻⁹⁰) filaments are infectious**

Spheroplasts of the indicated strain were transformed with pRS425 (*LEU2* 2 micron DNA) in the presence of freshly sonicated amyloid filaments of full length Ure2p^{albicans} (5 µg), Ure2p^{glabrata} (3 µg) or Ure2p^{cerevisiae} (30 µg), or filaments of Ure2p^{albicans} 1-90 (20 µg), Ure2p^{glabrata} 1-100 (3 µg), or soluble Ure2p^{albicans} 1-90 (20 µg) or Ure2p^{glabrata} 1-100 (6 µg). An extract of the [URE3alb] strain YHE1161 (100 µg) was also used. Leu+ clones were tested for Ade+. Ade+ clones were tested for curability on 3 mM guanidine. Asterisk indicates average taken from three separate infection experiments.

Recipient Strain	Infection Material	Number tested	Number Ade+	Number curable	Avg. % infection
BY302, <i>S. cerevisiae</i> URE2 ^{C. albicans}	none	303	17	0	0% *
	<i>Ca</i> Ure2p ¹⁻⁹⁰ filaments	295	59	21	7% *
	<i>Ca</i> Ure2p ¹⁻⁹⁰ soluble	144	0	0	0%
	BSA	144	3	0	0%
	<i>Sc</i> Ure2 ¹⁻⁸⁹ filaments	144	3	0	0%
	<i>Ca</i> Ure2p full length	144	3	0	0%
	YHE1161 lysate ([URE3alb])	310	56	41	13% *
BY304, <i>S. cerevisiae</i> URE2 ^{C. glabrata}	none	144	53	0	0%
	<i>Cg</i> Ure2p ¹⁻¹⁰⁰ filaments	144	38	0	0%
	<i>Cg</i> Ure2p ¹⁻¹⁰⁰ soluble	144	63	0	0%
	BSA	144	24	0	0%
	<i>Sc</i> Ure2p ¹⁻⁸⁹ filaments	144	33	0	0%
	<i>Cg</i> Ure2p full length	144	41	0	0%